Delivery Order SPE2DB25D3306-SPE2DB25FUCWR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,725.21 to AmerisourceBergen Drug Corp for HYSINGLA ER 20 mg tablets (60-count) on August 13, 2025, with completion scheduled for August 14, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. The award was made on...
- The Defense Logistics Agency awarded a delivery order valued at $1,628.83 to AmerisourceBergen Drug Corp for HYSINGLA ER 40 mg tablets (60-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, for the supply of Hysingla ER 20 mg tablets (60-count packages) under a firm fixed-price contract valued at $1,066.00. The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Hysingla ER 40 mg tablets (60-count units) with a contract value of $1,306.23. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery is scheduled for completion by October 21, 2025,...
- This federal contract award, valued at $2,434.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of 4,568,177,973 units of the prescription medication HYSINGLA ER 20 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at $999,999,999.00,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,030.88 firm fixed-price delivery order is for the supply of Hysingla ER 20 mg tablets, a medication used for pain management. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,070.48 firm fixed-price delivery order is for the supply of HYSINGLA ER 20 MG TABLET 60S, a prescription medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This delivery order was awarded by the Defense Logistics Agency Troop Support Medical (DLA) to Amerisourcebergen Drug Corp for the supply of 4561791558 Hysingla ER 40 mg tablets. Under the terms of the firm fixed price contract valued at $758.22, Amerisourcebergen will deliver 60 tablets to a facility located in Conshohocken, Pennsylvania, with performance required between August 11-14, 2023. No major subcontractors or set aside designations were identified. The DLA manages the global supply...
- This federal contract award, identified as SPE2DX15D3306|SPE2DX24FAEVF, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HYSINGLA ER 20 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $2,382.62 and a period of performance through April 2, 2024. This delivery order contract is a firm fixed price arrangement, with no set-aside designation used....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,030.71, is a delivery order for HYSINGLA ER TABS 40MG, a type of extended-release hydrocodone medication. The contract is not designated as a set-aside and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCWRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,504.08 to AmerisourceBergen Drug Corp for the supply of Hysingla ER 20 mg tablets (60-count units) on September 5, 2025, with an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. Hysingla ER, an extended-release opioid medication, represents one of the specialized pharmaceutical products delivered under this strategic contract vehicle that supports federal medical procurement needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 9/5/25 |